Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Pharmaceutics · 03.05.2023 · 15 (5) · 1399
DOI: 10.3390/pharmaceutics15051399 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.05.2023. Verfasst von Raquel Taléns-Visconti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 4…. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity’s olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability. Therefore, the physicochemical characteristics of formulations must be optimized by means of technological strategies. Among the strategies that have been explored, lipid-based nanosystems, particularly nanostructured lipid carriers, are promising in preclinical investigations with minimal toxicity and therapeutic efficacy due to their ability to overcome challenges associated with other nanocarriers. We review the studies of nanostructured lipid carriers for intranasal administration in the treatment of ATD. Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain.
- Molecular Topology and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain.
- Colloids Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain.
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Av. Vicent Andrés Estellés s/n, Burjassot, 46100 Valencia, Spain.
ORCID-Profile: Raquel Taléns-Visconti, Jesus Vicente de Julián-Ortiz, Amparo Nácher
Zitieren
APA
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023). Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics, 15(5), 1399. https://doi.org/10.3390/pharmaceutics15051399
Vancouver
Taléns-Visconti R, de Julián-Ortiz JV, Vila-Busó O, Diez-Sales O, Nácher A. Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics. 2023;15(5):1399. doi:10.3390/pharmaceutics15051399
BibTeX
@article{TalnsVisconti2023,
author = {Taléns-Visconti, Raquel and de Julián-Ortiz, Jesus Vicente and Vila-Busó, Ofelia and Diez-Sales, Octavio and Nácher, Amparo},
title = {Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1399},
doi = {10.3390/pharmaceutics15051399}
}
EUVIMED